Status:
COMPLETED
Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.
Lead Sponsor:
Toronto Rehabilitation Institute
Collaborating Sponsors:
Ontario Neurotrauma Foundation
St. Joseph's Healthcare Foundation
Conditions:
Acute Spinal Cord Injury.
Eligibility:
All Genders
16-60 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to find out if Risedronate works to prevent osteoporosis after spinal cord injury.
Eligibility Criteria
Inclusion
- Traumatic spinal cord injury less than 100 days.
- Must be able to swallow tablets and sit upright.
Exclusion
- Bilateral knee flexion contractures.
- Pregnant, lactating or post-menopausal females.
- Paget's disease, osteomalacia, steroid induced bone loss, untreated thyroid disease, iritis, uveitis, pancreatitis, gastritis, peptic ulcer or cholecystitis.
- Treatment in the last year with calcitonin, fluoride or anabolic steroid.
- Concurrent treatment with prednisone.
Key Trial Info
Start Date :
February 1 2000
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00150696
Start Date
February 1 2000
End Date
November 1 2005
Last Update
November 21 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamilton Health Sciences, Chedoke Site
Hamilton, Ontario, Canada, L8N 3Z5
2
Toronto Rehab, Lyndhurst Centre
Toronto, Ontario, Canada, M4G 3V9